HOME >> MEDICINE >> NEWS
Disoriented T cells cause liver disease

T cells activated in the gut during inflammatory bowel disease can be re-routed to the liver and cause chronic liver disease, according to Eksteen and colleagues in the December 1 issue of The Journal of Experimental Medicine.

A chronic liver disease known as primary sclerosing cholangitis (PSC) has been linked to inflammatory bowel disease (IBD) in the past. But the connection between the two disorders has been unclear, especially as the liver condition often develops years after IBD has resolved or the colon has been surgically removed. Eksteen and colleagues now show that T cells that were activated in the gut probably during IBD - are found in the livers of patients with PSC, but not in those of patients with other inflammatory liver diseases.

The authors explain this detour by showing that an attractant protein that normally directs T cells into the gut is aberrantly produced in the liver during PSC. T cells expressing the receptor for the protein are thus re-routed to the liver, although the authors do not know what triggers liver cells to make the attractant in the first place. T cells can survive as memory cells for many years after they are activated, and the authors believe this may explain how the liver disease can crop up years after IBD has resolved.


'"/>

Contact: Nikki Henry
henryn@rockefeller.edu
212-327-8366
Journal of Experimental Medicine
29-Nov-2004


Page: 1

Related medicine news :

1. Suppressing the cells that trigger cat allergy
2. Indiana University researchers closer to helping hearing-impaired using stem cells
3. Some brain cells change channels to fine-tune the message
4. Hopkins begins human trials with donor adult stem cells to repair muscle damaged from heart attack
5. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
6. Study suggests smoking while pregnant may increase chromosomal abnormalities in fetal cells
7. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
8. Smart immune cells kill more cancer
9. CK2 protein sustains colon cancer cells by sabotaging ability to commit suicide
10. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
11. PCBs, fungicide open brain cells to Parkinsons assault

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... will be speaking on how healthcare companies can use newly released government data ... health of a population and intervene and capture the value they create to ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/6/2016)... Aliso Viejo, CA (PRWEB) , ... February 06, 2016 , ... ... can quickly and easily add warm color grades to their footage. A LUT is ... changes every pixel's color to the corresponding color indicated by the table. By manipulating ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... ARBOR, Mich. , Feb. 8, 2016  The ... Arbor announced today that, as part of ... become one of the first hospitals in the U.S. ... Karin Muraszko , M.D., U-M,s chair of neurosurgery. ... chair of neurosurgery. --> The BrightMatter ...
(Date:2/8/2016)... , Feb. 8, 2016 Vestagen Technical ... high performance apparel for healthcare and other demanding applications, ... Chief Executive Officer. He replaces Dale Pfost , ... Chairman. Mr. Bold is also joining Vestagen,s Board of ... new class of active barrier technologies that combines fluid ...
(Date:2/8/2016)... 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced that the U.S. Food and Drug Administration ... (IND) application for SB-318, a single treatment strategy ... Type I (MPS I). The SB-318 IND application ... a Phase 1/2 clinical study (SB-318-1502) designed to ...
Breaking Medicine Technology:
Cached News: